$OPK

OPKO Health (OPK) issued $125M in senior secured notes to HealthCare Royalty, backed by royalties from mazdutide sales in China. The notes mature in 2044, with payments capped at 1.5x the royalty amount. OPKO reported Q2 revenue of $163.5M, up from $156.8M a year earlier, and a net loss of $8.4M, improved from a $148.4M loss. Diagnostics revenue fell to $74.5M due to asset sales. OPK repurchased $13.2M in stock while maintaining $314.4M in cash and securities.

OPKO Health is focusing on therapeutics, integrating ModeX Therapeutics and advancing programs in obesity, growth disorders, and oncology. The company expects significant clinical data in 12-18 months, with catalysts including updates on ModeX candidates and Merck's EBV vaccine. OPKO has $400M-$450M in cash, $125M from a China GLP-1 royalty, and plans a $200M share buyback.

Cocrystal Pharma (COCP) appointed Robert Sapirstein as CEO, with a compensation package tied to performance and equity. Phillip Frost, chairman of OPKO Health (OPK), invested $5 million in COCP. The company's board includes notable figures with pharmaceutical and corporate experience. COCP's antiviral candidate, CDI-988, is in Phase 1b trials with FDA Fast Track designation, targeting norovirus and other viruses. The company has $7.1 million in cash, providing a runway until Q1 2024.

OPKO Health (OPK) is positioned for growth due to RAYALDEE's performance and strategic partnerships. The company anticipates 23.3% earnings growth by 2026 and has outperformed the industry and S&P 500 year-to-date. However, risks include overdependence on RAYALDEE, clinical development risks, and macroeconomic pressures. OPK's shares have gained 17.4% YTD.

OPKO Health (OPK) trades at a discount to industry benchmarks, with improving operating trends but ongoing losses. Q2 2026 loss narrowed to $0.01 per share, and full-year loss is expected to improve. OPK has multiple clinical programs in development, with partnerships reducing funding burdens. Cash reserves stand at $314.4 million. Analysts suggest a wait-and-see approach due to mixed risk-reward profile.

OPKO Health (OPK) shares rose 12.4% in the past month due to improved operating metrics and upcoming clinical milestones. Q2 operating loss narrowed to $7M, gross profit increased to $80M, and BioReference turned profitable. Pharmaceutical revenues grew 59.8% YoY. However, OPK remains unprofitable, with risks tied to clinical execution and Medicare policy changes.

OPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 13, 2026, OPKO Health, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024 (the “Original Agreement”; and as amended by the Amendment, the “Amen

OPKO Health said it expanded its financing with HealthCare Royalty (HCRx), a KKR business, by issuing $125 million of senior secured notes. The notes are backed by OPKO’s mazdutide royalty interests from its Eli Lilly license and mature in 2044. OPKO expects non-dilutive capital and capped total payments at 1.5x funded, while retaining long-term royalty economics. Mazdutide is commercialized in China by Innovent Biologics.

OPKO Health reported Q2 2026 revenue of $163.58M, up from $156.81M, and a reduced net loss of $8.42M versus $148.44M a year earlier, though it remained unprofitable. The company also reiterated 2026 revenue guidance of $560M to $585M, shaping expectations for cost control and progress toward break-even.

Zacks upgraded OPKO Health (OPK) to a Zacks Rank #2 (Buy), citing rising earnings estimates. The Zacks Consensus Estimate increased 11.6% over the past three months. For FY ending Dec 2026, OPK is expected to earn -$0.26 EPS, unchanged year over year, according to Zacks.